Revolution Medicines, Inc.
RVMD
55 insider filings · Latest: Sep 29, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Sep 15 10:09 PM | Kelsey Stephen Michael | Proposed Sale | 5,415 | $203.77 | $1.1M | — | View → |
| Sep 15, 2026 | Sep 15 10:08 PM | Horn Margaret A | Proposed Sale | 4,830 | $203.77 | $984.2K | — | View → |
| Sep 15, 2026 | Sep 15 10:07 PM | Goldsmith Mark A | Proposed Sale | 13,603 | $203.77 | $2.8M | — | View → |
| Sep 15, 2026 | Sep 15 10:06 PM | Cislini Jeff | Proposed Sale | 3,272 | $203.77 | $666.7K | — | View → |
| Sep 15, 2026 | Sep 15 10:05 PM | Anders Jack | Proposed Sale | 3,939 | $203.77 | $802.7K | — | View → |
| Sep 11, 2026 | Sep 15 10:00 PM | Stephen Michael KelseySenior Advisor to the Chief Executive Officer | Sale | 92,531 | $202.36 | $18.7M | 291,876(D) | View → |
| Sep 10, 2026 | Sep 14 10:03 PM | Anthony ManciniChief Global Commercialization Officer | Sale | 15,448 | $204.16 | $3.2M | 43,890(D) | View → |
| Sep 11, 2026 | Sep 11 8:32 PM | STEPHEN KELSEY | Proposed Sale | 92,531 | $203.35 | $18.8M | — | View → |
| Sep 8, 2026 | Sep 10 9:52 PM | Lorence H. KimDirector | Sale | 17,090 | $209.82 | $3.6M | 0(I) | View → |
| Sep 10, 2026 | Sep 10 8:39 PM | ANTHONY MANCINI | Proposed Sale | 15,448 | $207.68 | $3.2M | — | View → |
| Aug 31, 2026 | Sep 2 8:30 PM | Lorence H. KimDirector | Sale | 56,000 | $203.24 | $11.4M | 17,090(I) | View → |
| Aug 31, 2026 | Aug 31 9:11 PM | Lorence H Kim | Proposed Sale | 73,090 | $207.88 | $15.2M | — | View → |
| Aug 21, 2026 | Aug 25 8:06 PM | Jeff CisliniGeneral Counsel | Sale | 56,894 | $209.24 | $11.9M | 55,907(D) | View → |
| Aug 21, 2026 | Aug 25 8:06 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Sale | 86,000 | $209.20 | $18.0M | 61,424(I) | View → |
| Aug 21, 2026 | Aug 21 8:38 PM | THE JONATHAN GOLDSMITH REVOCABLE TRUST | Proposed Sale | 3,000 | $211.74 | $635.2K | — | View → |
| Aug 21, 2026 | Aug 21 8:38 PM | THE REBECCA GOLDSMITH REVOCABLE TRUST | Proposed Sale | 3,000 | $211.74 | $635.2K | — | View → |
| Aug 21, 2026 | Aug 21 8:37 PM | MARK A GOLDSMITH | Proposed Sale | 80,000 | $211.74 | $16.9M | — | View → |
| Aug 21, 2026 | Aug 21 8:33 PM | JEFFREY TODD CISLINI | Proposed Sale | 75,894 | $211.74 | $16.1M | — | View → |
| Jun 29, 2026 | Jul 1 10:25 PM | Sushil PatelDirector | Sale | 5,580 | $187.99 | $1.0M | 21,656(D) | View → |
| Jun 29, 2026 | Jun 29 8:44 PM | SUSHIL PATEL | Proposed Sale | 5,580 | $182.08 | $1.0M | — | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | Apr 29 9:50 PM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 3,120 | $33.62 | 109,230(D) | View → |
| Apr 15, 2026 | Apr 17 11:26 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 120,000 | $4.73 | 424,085(D) | View → |
| Mar 25, 2026 | Mar 27 12:04 AM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 37,450 | $33.62 | 112,350(D) | View → |
| Mar 1, 2026 | Mar 4 2:11 AM | Xiaolin WangEVP, Clinical Development | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:10 AM | Lin WeiChief Medical Officer | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:09 AM | Stephen Michael KelseyPresident, Research and Development | Grant/Award | 47,600 | $102.02 | 47,600(D) | View → |
| Mar 2, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 30,000 | $4.09 | 47,708(D) | View → |
| Mar 1, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Grant/Award | 128,600 | $102.02 | 128,600(D) | View → |
| Mar 1, 2026 | Mar 4 2:08 AM | Margaret A HornChief Operating Officer | Grant/Award | 47,600 | $102.02 | 47,600(D) | View → |
| Mar 1, 2026 | Mar 4 2:08 AM | Jeff CisliniGeneral Counsel | Grant/Award | 32,500 | $102.02 | 32,500(D) | View → |
| Mar 1, 2026 | Mar 4 2:07 AM | Jack AndersChief Financial Officer | Grant/Award | 45,400 | $102.02 | 45,400(D) | View → |
| Feb 6, 2026 | Feb 10 10:30 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 24,010 | $0.54 | 144,493(D) | View → |
← Previous
Page 2 of 2